Ou se connecter avec
Twitter Twitter
Facebook Facebook
Apple Apple     
Ou se connecter avec
Twitter Twitter
Facebook Facebook
Apple Apple     


Temps Différé Nyse  -  22:03 05/12/2022
110.01 USD   -0.03%
02/12Merck pourrait conserver le brevet Keytruda avec une nouvelle formulation
01/12Mise à jour sectorielle : Les actions du secteur de la santé terminent en légère hausse
01/12Compass Therapeutics administre la dose au premier patient de l'essai de son immunothérapie CTX-471 combinée à Keytruda ; hausse des actions
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur MERCK & CO., INC.
02/12Merck Could Retain Keytruda Patent With New Formulation
02/12Compass Therapeutics, Inc. - a clinical-stage, oncology-focused biopharmaceutical compa..
01/12Sector Update: Healthcare Stocks Ending Slightly Higher
01/12Compass Therapeutics Doses First Patient in Trial of its CTX-471 Immunotherapy Combined..
01/12First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results ..
01/12Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th ..
30/11Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street
29/11Merck Declares Quarterly Dividend of $0.73 Per Share; Payable Jan. 9 to Shareholders of..
29/11Merck Announces First-Quarter 2023 Dividend
29/11Merck & Co., Inc. Announces Dividend for the First Quarter of 2023, Payable on January ..
29/11BigHat Biosciences, Inc. Announces Research Collaboration with Merck
23/11Merck & Co.'s Keytruda Combo Extends Survival in Late-stage Stomach Cancer Study
22/11Merck to Acquire Imago BioSciences Inc
22/11Merck's Keytruda Meets Primary Endpoint in Phase 3 Trial of Keytruda in Gastric Cancer ..
22/11Merck's Keytruda Hits Main Endpoint in Stomach Cancer Study
22/11Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in P..
22/11Merck Announces Phase 3 Keynote-859 Trial Met Primary Endpoint of Overall Survival in P..
22/11Merck & Co. To Buy Bone Marrow Disease-focused Imago BioSciences For $1.4 Billion
21/11Sector Update: Health Care Stocks Advance Modestly
21/11Trending : Merck to Acquire Imago BioSciences for $1.35 Billion
21/11Sector Update: Health Care Stocks Staying on Positive Ground
21/11Top Midday Gainers
21/11Merck Eyes Expanded Blood Disorder Drug Pipeline Via $1.35 Billion Buyout of Imago BioS..
21/11Global markets live: Walt Disney, Berkshire Hathaway, Tesla, Merck, ..
21/11Imago BioSciences Shares Take Flight on Takeover by Merck
21/11Waiting for a trend to emerge
21/11Sector Update: Health Care Stocks Mixed Pre-Bell Monday
21/11Rising Covid Cases in China Pressuring US Equities' Trading Sentiment
21/11Exchange-Traded Funds Preview: ETFs, Stock Futures Mixed A..
21/11Merck to Buy Imago for $36 A Share, More Than Double Friday's Close
21/11Merck to Acquire Imago BioSciences in $1.35 Billion Deal; Imago Shares Surge Pre-Bell
21/11Merck to Acquire Imago BioSciences, Inc.
21/11Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
18/11Global markets live: General Motors, Gap, Meta, Amazon, Tesla...
18/11Markets are still on a roller coaster ride
18/11Analyst recommendations: AbbVie, Bristol-Myers, Dominion Energy,..
17/11Schroder UK Public invests USD1.2 million in A2 Biotherapeutics
16/11UK Drug Pricing Agency Rejects Merck & Co.'s Molnupiravir, Four Other COVID-19 Treatmen..
15/11AstraZeneca and Merck - LYNPARZA in Combination with Abiraterone and Prednisone or Pred..
14/11Merck, AstraZeneca Prostate Cancer Treatment Receives European Medicines Agency Recomme..
14/11LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Rec..
14/11Astrazeneca and Merck Announces Lynparza® in Combination with Abiraterone and Prednison..
14/11AstraZeneca's Three Cancer Therapies Backed for Expanded Approval in EU
11/11Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-i..
11/11Portage biotech presents updated data on the phase 1/2 trial evaluating port-2 at the s..
10/11Insider Sell: Merck & Co.
10/11Immutep Reports 'Compelling' Data from Mid-Stage Lung Cancer Trial; Shares Rise Midday
09/11Insider Sell: Merck & Co.
08/11Portage Biotech, Merck to Collaborate on Cancer Study
08/11Merck & Co.'s HPV Shot Cuts Rates of Cervical, Non-cervical Diseases in Real-world Use
07/11Insider Sell: Merck & Co.
07/11Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highligh..
07/11Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women ..
07/11Merck Announces Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Di..
03/11Insider Sell: Merck & Co.
03/11MERCK & CO., INC. Management's Discussion and Analysis of Financial Condition and Resu..
03/11Tranche Update on Merck & Co., Inc.'s Equity Buyback Plan announced on October 25, 2018..
03/11IO Biotech Teams Up With Merck to Evaluate IO102-IO103 Combined With Keytruda to Treat ..
03/11IO Biotech, Inc. Announces New Clinical Collaboration with Merck & Co., Inc
02/11Transgene Discloses Positive Interim Analysis Results of Phase 2 Trial of TG4001, Avelu..
01/11Insider Sell: Merck & Co.
01/11Insider Sell: Merck & Co.
01/11Insider Sell: Merck & Co.
01/11Insider Sell: Merck & Co.
01/11Insider Sell: Merck & Co.
01/11Insider Sell: Merck & Co.
01/11Veeva and Merck Form Long-Term Strategic Partnership
01/11Veeva and Merck Form Long-Term Strategic Partnership
31/10Bristol Myers Squibb's Phase 3 Anemia Drug Trial Meets Endpoints
28/10Merck & Co. Boosts FY22 Sales Guidance Amid Growth In Oncology, Vaccines Sales
27/10MÄRKTE USA/Uneinheitlich - Caterpillar und Boeing treiben Dow
27/10Global markets live: Boeing, Credit Suisse, Daimler, Ford, Unilever...
27/10Trending : Merck Raises Outlook After 3Q Beats Expectations
27/10MÄRKTE USA/Uneinheitlich - Berichtssaison macht Kurse
27/10Sector Update: Health Care Stocks Rally Premarket Thursday
27/10Tech stocks lose their mojo
27/10Drugmaker Merck tops 3Q forecasts as Keytruda sales jump 20%
27/10MÄRKTE USA/Etwas leichter erwartet - Zurückhaltung vor Geschäftszahlen
27/10US-Pharmakonzern Merck erhöht abermals die Prognose
27/10Merck Q3 Non-GAAP Earnings, Revenue Increase; Lifts Full-Year Outlook
27/10Merck : 3Q22 Merck Earnings Presentation
27/10Merck : Q3 Earnings Snapshot
27/10Merck & Co., Inc. : Results of Operations and Financial Condition, Change in Directors or ..
27/10GUIDANCE: (MRK) MERCK & CO. Sees Fiscal Year 2022 Revenue Range $58.50B - $59B
27/10GUIDANCE: (MRK) MERCK & CO. Sees Fiscal Year 2022 EPS Range $7.32 - $7.37
27/10Earnings Flash (MRK) MERCK & CO. Posts Q3 Revenue $14.96B
27/10Earnings Flash (MRK) MERCK & CO. Posts Q3 EPS $1.85
27/10Merck Announces Third-Quarter 2022 Financial Results
27/10Merck Provides Earnings Guidance for the Year 2022
27/10Merck & Co., Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
27/10Merck Lowers Earnings Guidance for the Year 2022
27/10MARKT USA/Wenig verändert erwartet - Zögern vor Zahlen
27/10Merck Names Robert Davis Board Chairman
27/10Bolsa de Madrid: Wall Street abandonado por sus estrellas
27/10Merck & Co.'s CEO To Take Over Chairman Role In December
26/10Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
26/10Merck Announces Board Changes
26/10Immutep to Proceed With Head, Neck Squamous Cell Carcinoma Trial Without Modifications
26/10PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head..
26/10Merck & Co. to Donate Investigational Ebola Vaccine for Clinical Testing in Uganda
Prochain événement sur MERCK & CO., INC.